Digestive and Liver Disease 47 (2015) 181190

Contents lists available at ScienceDirect

Digestive and Liver Disease

journal homepage: www.elsevier.com/locate/dld

Review Article

Nonalcoholic fatty liver disease: A precursor of the metabolic

syndrome
Amedeo Lonardo a, , Stefano Ballestri b , Giulio Marchesini c , Paul Angulo d , Paola Loria a
a
AUSL Modena and University of Modena and Reggio Emilia, Department of Biomedical, Metabolic and Neural Sciences, Division of Internal Medicine,
NOCSAE Baggiovara, Modena, Italy
b
AUSL Modena, Department of Internal Medicine, Division of Internal Medicine, Hospital of Pavullo, Pavullo nel Frignano, Italy
c
Alma Mater Studiorum University, Unit of Metabolic Diseases and Clinical Dietetics, Bologna, Italy
d
University of Kentucky, Division of Digestive Diseases & Nutrition, Section of Hepatology, Medical Center, Lexington, KY, USA

a r t i c l e

i n f o

Article history:
Received 30 April 2014
Accepted 21 September 2014
Available online 18 November 2014
Keywords:
Dissociation
Insulin resistance
Natural history
Pathogenesis

a b s t r a c t
The conventional paradigm of nonalcoholic fatty liver disease representing the hepatic manifestation of
the metabolic syndrome is outdated. We identied and summarized longitudinal studies that, supporting the association of nonalcoholic fatty liver disease with either type 2 diabetes mellitus or metabolic
syndrome, suggest that nonalcoholic fatty liver disease precedes the development of both conditions.
Online Medical databases were searched, relevant articles were identied, their references were further
assessed and tabulated data were checked.
Although several cross-sectional studies linked nonalcoholic fatty liver disease to either diabetes and
other components of the metabolic syndrome, we focused on 28 longitudinal studies which provided
evidence for nonalcoholic fatty liver disease as a risk factor for the future development of diabetes.
Moreover, additional 19 longitudinal reported that nonalcoholic fatty liver disease precedes and is a risk
factor for the future development of the metabolic syndrome.
Finally, molecular and genetic studies are discussed supporting the view that aetiology of steatosis
and lipid intra-hepatocytic compartmentation are a major determinant of whether fatty liver is/is not
associated with insulin resistance and metabolic syndrome.
Data support the novel paradigm of nonalcoholic fatty liver disease as a strong determinant for the
development of the metabolic syndrome, which has potentially relevant clinical implications for diagnosing, preventing and treating metabolic syndrome.
2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.

1. Introduction
Steatosis and steatohepatitis, in the absence of competing aetiologies such as high alcohol intake, hepatitis C virus (HCV) infection,
drugs and other endocrine disorders, are both part of the nonalcoholic fatty liver disease (NAFLD) spectrum [13]. NAFLD may either
occur in the absence of fatty changes and is often alluded to either
as cryptogenic or nonalcoholic steatohepatitis (NASH)-cirrhosis
[4,5] or encompass hepatic and extra-hepatic complications, from
hepatocellular carcinoma to atherosclerosis [6]. NAFLD is presently
recognized as one the most common causes of altered liver tests,
of end-stage liver disease requiring liver transplantation, and is

Corresponding author at: Division of Internal Medicine, NOCSAE Baggiovara,

Via Giardini 1135, 4100 Modena, Italy. Tel.: +39 0593961807; fax: +39 0593961322.
E-mail addresses: a.lonardo@libero.it, a.lonardo@ausl.mo.it (A. Lonardo).

frequently associated with the constellation of clinico-laboratory

features that comprise the metabolic syndrome [79].
The metabolic syndrome is a cluster of cardio-metabolic conditions, generally triggered by an expansion of the adipose visceral
tissue [10], which include insulin resistance with or without
impaired glucose metabolism and type 2 diabetes (T2D) atherogenic dyslipidemia [low high density lipoprotein (HDL)-cholesterol
and high triglycerides], and high blood pressure [11]. The present
denition of metabolic syndrome, at variance with one of its earliest
proposals [12], does not include hepatic steatosis despite evidence
supporting this association [13]. The existence and the utility of
metabolic syndrome as a separate entity has been challenged by
some experts [14]. Moreover, it remains controversial whether the
presence of the full-blown syndrome really adds to the cardiovascular risk dictated by its individual components, particularly T2D
[15,16]. Nevertheless, the single traits of the metabolic syndrome
tend to aggregate in the same individuals and, more importantly,
the presence of each of them often anticipates the appearance of

http://dx.doi.org/10.1016/j.dld.2014.09.020
1590-8658/ 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.

182

A. Lonardo et al. / Digestive and Liver Disease 47 (2015) 181190

Table 1
Nonalcoholic fatty liver disease and metabolic syndrome the original spectrum of similarities.
Steatosis

Metabolic syndrome

Epidemiology
Prevalence in the general population
Prevalence grows with age
Males more affected

Up to 25% of adults
Yes
Yes (adults, children)

Epidemic in the elderly

Strongly age-dependent
Yes

Anthropometry
Association with central obesity

Abdominal adiposity is an independent predictor

Visceral fat is correlated with Insulin response and dyslipidemia

Metabolism Association with

Hyperinsulinemia
Hypertension
Obesity
Hypertriglyceridemia
Low HDL Cholesterol

Documented
In drinkers and non-drinkers
Yes
Yes
Circumstantial Evidence

Pathogenic mainstay
Yes
Yes
Yes
Yes

Clinical features
Systemic disease
Accelerated atherogenesis
Response to diet and/or exercise

Yes
Circumstantial Evidence
In the obese

Yes
Yes
Yes

Experimental pathology
Animal Models (rat)

Atherogenic diet induces steatosis

Hypertensive animals have hyperinsulinemia and hypertriglyceridemia

Adapted from Lonardo [20].

additional components over time [17]. This, together with the possible progression to organ failure and of the development of some
cancer types, including primary liver cancer [9,11,18,19], makes
metabolic syndrome a relevant condition in clinical practice and a
major public health concern worldwide.
In 1999, European researchers [2022] provided biological, clinical and epidemiological evidence for the theory that NAFLD should
be regarded as the hepatic manifestation of the metabolic syndrome (Table 1) [20]. Since then, a chicken and egg scientic
debate has arisen, concerning the primacy of metabolic syndrome
(and insulin resistance) over NAFLD or, conversely, of NAFLD
over the metabolic syndrome [23]. Moreover, while most studies
acknowledge NAFLD to be a risk factor for T2D [24], the notion that
NAFLD anticipates the future development of components of the
metabolic syndrome other than T2D is far less accepted, although
it has been suggested by few authors [23,25,26] mainly based on
their expert opinion.
In our systematic review of the literature, we discuss all available data supporting the view that NAFLD, rather than being
a mere manifestation of the metabolic syndrome is indeed a
necessary precursor of the future development of metabolic syndrome in humans. To this end, further to identifying all relevant
cross-sectional studies, we specically address the evidence from
prospective studies showing that NAFLD is an independent risk factor for the future development of both T2D and other components
of the metabolic syndrome. Methodological limitations of such data
are briey analysed. Finally, we discuss how some examples of
dissociation of NAFLD from metabolic syndrome seemingly contradicting our thesis eventually conrm the general paradigm of
NAFLD being a precursor of the metabolic syndrome.
2. Research strategy
The PubMed data base was manually searched for the following terms: Metabolic syndrome; Type 2 Diabetes; Obesity;
Dyslipidemia Hyperlipidemia; Insulin resistance; Predictor;
Fatty liver; Follow-up; Association and Dissociation. The
research was updated at the 28th of April 2014. Further bibliographic updates were performed whenever needed during the
revision process.
All of the identied articles and their references were further
checked in duplicate in order to identify appropriate articles. Pertinent studies were identied as a result of the agreement two

investigators, who also tabulated the methods and chief ndings

of the selected material.
The accuracy of the tabulated data was independently performed by all authors.
3. Association of NAFLD with other conditions
3.1. Type 2 diabetes
Many cross-sectional studies demonstrate that NAFLD is associated with insulin resistance/pre-diabetes/T2D [2739]. Despite
a variable follow-up range, data appear consistent in disclosing
that the NAFLD pathway to T2D follows a route characterized
by insulin resistance developing at various anatomic sites, notably
including hepatic insulin resistance. Interestingly, the NAFLDT2D association occurs irrespective of potential confounders and
particularly obesity and moderate alcohol drinking, suggesting
that NAFLD may closely mirror the development of fatty pancreas disease [40] and thus reect tissue lipotoxicity. Moreover, a
quantitative relationship links fasting plasma glucose with NAFLD
prevalence: the higher the former, the higher the latter [29].
However, widely acknowledged predictors of T2D in non-NAFLD
populations (such as high fasting glucose and low HDL-cholesterol
and adiponectin, mirroring insulin resistance) and low physical
activity also predict T2D in NAFLD suggesting that NAFLD probably amplies the physiological determinants of T2D. Finally, most
ndings appear to be conrmed irrespective of ethnicity (e.g.
T2D-prone Asians vs. Caucasians) and of the diagnostic technique
followed to capture NAFLD, spanning from the most invasive or
accurate tests (liver histology, magnetic resonance imaging) to the
most insensitive (liver tests), via the most widely performed ultrasonography scanning.
However, the above studies [2739] are cross-sectional. Accordingly, they do not rule out the possibility that primarily impaired
gluco-regulation may eventually result in the development of
NAFLD. In order to clarify this issue, in Supplementary Table S-1
the studies showing NAFLD as a risk factor for the future development of T2D were summarized. Eleven out of 12 studies were
conducted in Far East, most of them from Korea. With such a
limitation, they conrm that NAFLD is an independent risk factor
for the development of T2D, although conrmation from Western
countries appears necessary. Moreover, the diagnostic technique
used to detect NAFLD may lead to different results. For instance,

A. Lonardo et al. / Digestive and Liver Disease 47 (2015) 181190

183

Table 2
Nonalcoholic fatty liver disease and metabolic syndrome the expanded spectrum of similarities.

Increasing serum uric acid levels

High fructose consumption

TSH

Bile acids

Increased physical exercise

Light to moderate alcohol consumption

Caffeine

Smoking
Altered sleep physiology

Brown adipose tissue

NAFLD

Metabolic syndrome

Are associated with increased prevalence and histological

severity of NAFLD [6668]
Is associated with increased prevalence of NAFLD and
increased NASH severity [83,84] owing to enhanced
lipogenesis, hepatic brosis, inammation, endoplasmic
reticulum stress and lipoapoptosis [85]
Clinical/subclinical hypothyroidism and elevated TSH,
though in the normal range, are associated with increased
prevalence and histological severity of NAFLD [8992]

Are associated with increased prevalence and incidence of

metabolic syndrome [6982]
Increases the risk of developing metabolic syndrome and
its components [8688]

Participate in the pathogenesis of NAFLD through

regulating hepatic nutrients and energy homeostasis;
stimulating GLP-1 secretion in the small intestine and
energy expenditure in brown adipose tissue and skeletal
muscle [98]. UDCAs role in NASH management, however,
remains controversial [99,100]
Protects from NAFLD, independent of weight loss
[104108] and improves histological steatosis [109]
Is associated with a reduced prevalence of NAFLD and
NASH [3,117120]

Seemingly protects from NAFLD and liver brosis

[133136] without decreasing the risk of NASH [134,135].
Benecial liver outcomes are mediated by antioxidant,
antibrogenic, antinammatory, insulin sensitizing,
lipolytic, cyto, and genoprotective activity [137142]
Risk factor for the development of NAFLD and its brotic
progression [146148]
Shorter sleep duration and severe obesity-related
obstructive sleep apnoea are independently associated
with development and histological severity of NAFLD
[150152]
Subjects maintaining active brown adipose tissue are
protected from NAFLD [157]

Intestinal microbiota

May promote NASH by several mechanisms including

improved energetic efciency; increased gut permeability
and production of lipopolysaccharides with activation of
the innate immune system; altered bile acids pool;
reduced bioavailability of dietary choline and increased
endogenous ethanol production [162172]

Vitamin D deciency

Is associated with NAFLD development and the severity of

hepatic histological changes [189192]

There is a close dose-dependent relationship between

increasing TSH and incident/prevalent metabolic
syndrome in various ethnicities and across different
age-groups [9397]
Are powerful regulators of metabolism and induce
increased thermogenesis, protect from diet induced
obesity, hepatic lipid accumulation, and increased plasma
triglyceride and glucose levels via activation of Bile acids
receptors (FXR and TGR5) [101103]
Protects from the development of and cures established
metabolic syndrome [110116]
Seemingly protects from the development of at least some
components of the metabolic syndrome. Conversely, heavy
drinking increases the risk of metabolic syndrome
[121132]
Reported to be a protective factor from metabolic
syndrome, maybe through a lipolytic effects of caffeine on
adipocytes [143145].

Positively and reversibly associated in a dose-dependent

manner with the risk of metabolic syndrome [149]
Altered sleeping time duration and continuity are
associated with increased risk for the metabolic syndrome
[150,153156]
The presence of brown adipose tissue is inversely related
to BMI. Brown adipose tissue activity plays a role in
constitutional leanness without affecting glucose
metabolism [158161]
Plays a signicant role in the development of metabolic
syndrome via increased energy harvesting, metabolic
endotoxinemia; control of lipid and glucose metabolism
via the composition of bile-acid pools and the modulation
of FXR and TGR5 signalling; modulation of intestinal
microbial composition by innate immune system;
brain-gut enteric microbiota axis [170,173188]
May increase the risk for metabolic syndrome, type 2
diabetes, insulin resistance, obesity, hypertension and
cardiometabolic outcomes [193198]

List of abbreviations: BMI, body mass index; FXR, farnesoid X receptor; GLP-1, glucagon-like peptide-1; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcholic steatohepatitis; TGR5, membrane-type G-protein-coupled receptor for bile acids; TSH, thyroid stimulating hormone; UDCA, ursodeoxycholic acid.

the less specic gamma-glutamyltransferase (GGT) values more

accurately predict the development of T2D than aminotransferase
levels. Similarly, the ultrasonographic severity of NAFLD is associated with increasing risks of T2D and, notably, NASH (more than
simple steatosis) appears to be more closely associated with T2D.
However, such a conclusion was challenged by a subsequent metaanalysis by Musso et al. showing that the risk of developing T2D is
increased to a similar extent in both steatosis and NASH [41].
3.2. Other components of metabolic syndrome
Data reporting NAFLD as a risk factor for either some individual components of metabolic syndrome [arterial hypertension
[42,43] and dyslipidemia [44]] or the full-blown syndrome are
less established than NAFLD progression to T2D. Many crosssectional studies support the view that NAFLD is associated with
the metabolic syndrome [13,22,4564].
Data universally conrm the strong NAFLD-metabolic syndrome
association in humans. In addition, although each component of
metabolic syndrome [including serum uric acid, not included in
the diagnostic criteria but clearly a component of the syndrome

from a pathophysiological point of view [8]] is independently associated with NAFLD, a few features (visceral obesity, dyslipidemia
and insulin resistance/T2D) are more closely related to NAFLD.
The association of NAFLD with the metabolic syndrome appears
to be stronger in lean than in obese individuals, especially in
women. NAFLD specically anticipates the presence of metabolic
disorders and independently predicts insulin resistance, identifying those individuals with insulin resistance who may be missed by
metabolic syndrome criteria in certain populations. The frequency
of metabolic syndrome signicantly increases with quintiles of ALT
and GGT, even within the normal range of these enzymes [51].
Moreover, T2D and hypertriglyceridemia are more commonly associated with raised hepato-biliary enzymes, and particularly GGT
[65], an association which appears to be independently mediated
by insulin resistance. In turn, the presence of metabolic syndrome
is associated with the development of brosis or NASH.
Again, association in cross-sectional studies does not provide
evidence as to which condition comes rst. In order to address this
issue, studies supporting the view that NAFLD precedes the development of metabolic syndrome are summarized in Supplementary
Table S-2.

184

A. Lonardo et al. / Digestive and Liver Disease 47 (2015) 181190

Collectively, they suggest that NAFLD, either diagnosed via surrogate indices or by ultrasonography, antedates the presence of
several components of metabolic syndrome, not only of T2D. This
association is largely regulated by the presence of insulin resistance. However, in 13 out of 15 such studies, NAFLD was diagnosed
on surrogate laboratory indices, on ultrasonographic ndings in
two and in none by the gold standard liver biopsy technique. Moreover, the diagnostic criteria tended to be heterogeneous and given
that enlarged waist circumference is both a main pathogenic key
for NAFLD and is central for the diagnosis of metabolic syndrome, it
is virtually impossible to rule out the possibility that visceral obesity links the development of both NAFLD and metabolic syndrome.
Finally, no specic traits of the metabolic syndrome (dysglicemia,
dyslipidemia, high blood pressure and central obesity) are mandatory for the development of the full-blown metabolic syndrome
(Supplementary Table S-2).

4. Does NAFLD precede metabolic syndrome? Insulin

resistance as a major player
Compared to our historical perception (Table 1), present
understanding of the epidemiological, clinical and pathogenic similarities between NAFLD and the metabolic syndrome has expanded
to a substantial extent. Accordingly, it presently embraces a large
number of risk/protective factors and biological mediators, i.e.,
serum uric acid, fructose, TSH, bile acids, physical exercise, alcohol, caffeine, smoking, altered sleep physiology, brown adipose
tissue, intestinal microbiota and vitamin D deciency (Table 2)
[66198]. Associations of these factors with NAFLD may mirror
different pathophysiological mechanisms underlying the natural
course leading from NAFLD to metabolic syndrome.
Phylogenetically evolved to promote survival, insulin resistance
will lead to the deleterious manifestations of the metabolic syndrome whenever inappropriately activated by unhealthy lifestyles
[199]. Clinically, insulin resistance is dened as the critical
connector linking stress, visceral adiposity, and decreased cardiorespiratory tness with increased cardiovascular disease [14].
Biologically, elevated fasting glucose will result from hepatic
insulin resistance, whereas increased free fatty acids (FFA) concentrations are the expression of peripheral insulin resistance
[200]. At molecular level, insulin resistance invariably results from
the interaction of cell membrane receptors with either excess
nutrients or inammatory cytokines. Such an interaction will
trigger JNK and IKK, protein kinase C, S6K, mTOR, and ERK. All
these pathways are involved in the amplication of inammation, phosphorylation of insulin receptor substrates 1 and 2, stress
of endoplasmic reticulum, production of reactive oxygen species
and mitochondrial dysfunction [201]. Once triggered, this vicious
circle of systemic metabolic dysfunction of insulin and leptin
action tends to self-perpetuate [202]. Impaired intracellular insulin
signalling will eventually result in perturbed Glut-4-mediated
glucose uptake with preserved/potentiated MAP kinase-mediated
mitogenesis/cell survival pathways [200].
First proposed, as early as 1988, as the underlying factor in
the metabolic syndrome [203], insulin resistance undoubtedly
plays a major role in the pathophysiology of the metabolic syndrome [204]. The expansion of visceral adipose tissue will result
in the liver being overowed with FFA, thus leading to steatosis. A fatty liver, in turn, is the prerequisite for the development
of highly atherogenic dyslipoproteinemia featuring low HDLcholesterol, hypertriglyceridemia and increased small and dense
low-density lipoprotein (LDL) particles, as well as for fasting hyperglycemia, which stimulates the pancreas to compensatory insulin
over-secretion. Collectively, increased FFA concentrations, hyperglycemia and hyper-insulinemia may directly (or indirectly via

sympathetic over-activation) promote arterial hypertension and

ectopic deposition of fat in extra-adipose tissues. More importantly,
the described metabolic derangements are intimately associated
with increased production of brinogen, PAI-1, TNF-alpha, IL-6 and
decreased adiponectin levels. A subclinical pro-inammatory proatherogenic state will ensue, which is a major biological feature of
insulin resistance and a typical hallmark of the metabolic syndrome
[204].
While most individuals with NAFLD have insulin resistance
[13,205], only a minority of those with NAFLD exhibit the fullblown metabolic syndrome [206]. This nding most likely results
from fatty liver being a precursor [207] and a necessary prerequisite
to the development of progressive metabolic disease [23,208210].
Adipose tissue is the only physiologic reservoir of fatty acids, and
the accumulation of fat in the extra-adipose tissues may be tissuedamaging and eventually lead to organ dysfunction (a concept
alluded to as lipotoxicity). Data from a mouse model support the
view of fatty liver being a protective mechanism which prevents
progressive liver damage in NAFLD [211] suggesting that esterication into triglycerides might well be a mechanism which detoxies
histologically damaging FFA in the liver. Further evidence for the
concept that fatty liver is an adaptive phenomenon derives from its
occurrence in animal species other than humans suggesting that
steatosis is evolutionarily useful [212215].
Characterization of the role of PKC is probably the most exciting
progress in our understanding of the molecular pathogenesis of the
connection linking liver steatosis with hepatic insulin resistance.
In obese humans, fatty substrates such as diacylglycerol account
for 64% of the variability of insulin sensitivity via the activation
of PKC [216], which impairs insulin signalling as shown in rats
using antisense oligonucleotides [217]. Of outstanding interest, the
intracellular compartmentation of diacylglycerol dictates whether
or not PKC will translocate to the plasma membrane so promoting
hepatic insulin resistance [218]. Stated otherwise, various classes of
lipids (such as mono-, di- and tri-acylglycerol) sequestered within
lipid droplets/Endoplasmic reticulum fraction are deemed to be
innocuous as far as the development of hepatic insulin resistance
is concerned in the CGI-58 knockdown mouse model [219].
In humans, however, most cases of NAFLD are strongly
associated with insulin resistance. In agreement, diacylglycerol
acyltransferase 2 (DGAT2), the enzyme catalysing the nal step
in the biosynthesis of triglycerides, may link glycemia and triglyceridemia [220]. These data are fully consistent with the view that
the development of a fatty liver occurs upstream in the chain of
metabolic events eventually leading to the development of the
metabolic syndrome [210] and help understand the mechanistic
reason why subjects with NAFLD were 1.6 times more likely to
develop T2D than NAFLD-free persons in a recent 3-year followup Japanese study [221]. Of clinical interest, a growing number
of components of the metabolic syndrome are associated with an
increased risk of hepatic brosis in the individual patient [222]
thus enabling the identication of those who should undergo liver
biopsy [223]. In particular, data have shown that a vicious circle links T2D and liver disease, with NAFLD contributing to the
future development of T2D and the latter triggering progressive
liver injury [40]. Fatty pancreas develops in the setting of metabolic
syndrome, carrying amazing similarities to NAFLD in terms of organ
inammation, end-stage organ failure, susceptibility to cancer and
post-surgical complications [224].
Lipid droplets display a unique protein repertoire including
Adipophilin and TIP47 which, further to fatty adipocytes, are
expressed in lipid droplets of hepatic stellate cells. Perilipin, once
deemed to be characteristic of lipid droplets in the adipocytes and
steroidogenic cells, is expressed de novo in liver cells of steatotic
liver in humans [225]. The nding that the distribution of perilipin
is predominantly perivenous in the liver lobule [225] may suggest

A. Lonardo et al. / Digestive and Liver Disease 47 (2015) 181190

185

Fig. 1. Primacy of nonalcoholic fatty liver disease over metabolic syndrome. Based on epidemiological and biological data discussed in the text, the cartoon schematically
illustrates the theory of nonalcoholic fatty liver disease being the precursor of metabolic syndrome. Although not included in current diagnostic criteria of metabolic
syndrome, uric acid is denitely a trait of the metabolic syndrome constellation from a pathophysiological point of view and a determinant of development and progression
of nonalcoholic fatty liver disease, as discussed in Table 2. The key-role of lipid droplets in potentially protecting fatty liver from developing insulin resistance is highlighted
based on recently published data [218,219].

a specic role of this protein in the four-step model of histogenetic events originally proposed by Wanless to account for NASH
pathogenesis and its progression to cirrhosis via hepatic venular
obstruction [226]. Perilipin has been conrmed by following studies as one of the most prominent upregulated genes in NAFLD [227].
In summary, alterations in the regulation of lipid droplets physiology and metabolism inuence the risk of developing metabolic
diseases such as T2D and NAFLD [227]. Fig. 1 illustrates the hypothesis that NAFLD is a precursor of the metabolic syndrome via insulin
resistance resulting from PKC activation which conceivably occurs
in most cases of NAFLD in humans.
If the general rule is that steatosis and insulin resistance are
associated, are there any examples of such two conditions being
dissociated from each other?
5. Dissociation of NAFLD from insulin resistance and the
metabolic syndrome
The rst clinical evidence for conditions where high-grade
steatosis occurs without insulin resistance or low-grade liver fat
content is nonetheless associated with insulin resistance was
reported in 2006. This conclusion was reached by comparing insulin
resistance (assessed by HOMA-IR) and steatosis grade in three naturally occurring different conditions displaying a variable extent
of steatosis: familial hypobetalipoprotenemia (FHBL), NAFLD and
steatosis (evaluated histologically) associated with HCV infection
[228]. In 2010 Amaro et al. measuring insulin resistance with the
hyperinsulinemic-euglycemic clamp procedure coupled with glucose tracer infusion and liver fat content with magnetic resonance
(MR) spectroscopy, conrmed the results in FHBL individuals [229].
Of interest, circumstantial evidence suggests that FHBL is associated with progressive liver disease only in those patients featuring
components of the metabolic syndrome [230].
Consistent with the potential occurrence of steatosis dissociated from insulin resistance, Kantartzis et al. reported that single
nucleotide polymorphisms in the diacylglycerol acyltransferase 2

(DGAT2) gene accounted for variability in liver fat content rather

than for insulin resistance. These results conrm and extend
to humans the nding that DGAT2 mediates the dissociation
between fatty liver and insulin resistance [231]. The same group
of researchers reported that the patatin-like phospholipase 3 gene
(PNPLA3) is a key factor in determining whether fatty liver is associated or not with metabolic derangements such as insulin resistance
[232].
Finally, PNPLA3 gene polymorphisms have recently been associated with those NAFLD cases occurring in the absence of metabolic
syndrome [233], indirectly suggesting that genetic conditions
which promote the development of fatty changes in the liver may
occur independently of insulin resistance.
A detailed survey of those studies demonstrating a dissociation of fatty liver and T2D in both experimental conditions and
humans has recently been published by Sun et al. [234]. Collectively, ndings from both genetically engineered animal models
and humans with genetic conditions conrm the view that the aetiology of steatosis is a major determinant of whether steatosis is
associated (such as seen in most cases of NAFLD observed in clinical practice) or dissociated from insulin resistance and features
of the metabolic syndrome (such as seen in NAFLD occurring in
carriers of PNPLA3 gene polymorphisms and in FHBL individuals)
[228,233,234]. As schematically depicted in Fig. 1, compartmentation of intrahepatocytic lipids may potentially account for the end
result of NAFLD being either associated or dissociated from insulin
resistance [218,219] and therefore from the risk of developing
the metabolic syndrome. Once fully characterized in humans, the
sub-cellular mechanisms of dissociation of steatosis from insulin
resistance may become a preferential target for the prevention and
management of insulin resistance and the metabolic syndrome.
6. Conclusions
A systematic review of the literature shows that the presence of
NAFLD is intimately linked with the metabolic syndrome, including

186

A. Lonardo et al. / Digestive and Liver Disease 47 (2015) 181190

T2D. Moreover, NAFLD is a strong determinant for the future development of the metabolic syndrome. This is likely to occur as a
result of its being a key factor associated with insulin resistance
in naturally occurring conditions in humans. Exceptions to such
a theory are found in some genetic polymorphisms where the
steatosis-insulin resistance-metabolic syndrome triad is dissociated in humans. The molecular biology of events dictating NAFLD
being associated with or dissociated from insulin resistance is
increasingly being elucidated.
On these grounds, the diagnostic importance of NAFLD as a criterion for the presence, as well as for risk of future development
of metabolic syndrome, needs to be emphasized. From a therapeutic point of view, those pathogenic-based interventions aimed
at reversing NAFLD are likely to be a rational approach in the
prevention and treatment of hepatic insulin resistance, metabolic
syndrome and related complications.
Conict of interest
None declared.
Acknowledgement
This article is devoted to the memory of late Professor Paola
Loria, M.D. The authors are grateful to Dr Leon Adams for invaluable
advice and thank Elisa Gibertini for kind assistance as a graphic
artist.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.dld.2014.09.020.
References
[1] Angulo P. Non-alcoholic fatty liver disease. New England Journal of Medicine
2002;346:122131.
[2] Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clinics in Liver
Disease 2007;11:10517.
[3] Nascimbeni F, Pais R, Bellentani S, et al. From NAFLD in clinical practice to
answers from guidelines. Journal of Hepatology 2013;59:85971.
[4] Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and
the natural history of non-alcoholic fatty liver disease. Journal of Hepatology
2004;40:57884.
[5] van der Poorten D, Samer CF, Ramezani-Moghadam M, et al. Hepatic fat loss in
advanced non-alcoholic steatohepatitis: are alterations in serum adiponectin
the cause? Hepatology 2013;57:21808.
[6] Lonardo A, Sookoian S, Chonchol M, et al. Cardiovascular and systemic
risk in non-alcoholic fatty liver disease atherosclerosis as a major player
in the natural course of NAFLD. Current Pharmaceutical Design 2013;19:
517792.
[7] Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. Journal of
Hepatology 2001;35:1959.
[8] Lonardo A, Caldwell SH, Loria P. Clinical physiology of NAFLD: a critical
overview of pathogenesis and treatment. Expert Review of Endocrinology
& Metabolism 2010;5:40323.
[9] Wong RJ, Cheung R, Ahmed A. Non-alcoholic steatohepatitis is the most
rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. Hepatology 2014;59:218895.
[10] Palaniappan L, Carnethon MR, Wang Y, et al. Predictors of the incident
metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study.
Diabetes Care 2004;27:78893.
[11] Eckel RH. The metabolic syndrome. Lancet 2010;375:1813.
[12] Haller H. Epidemiology and associated risk factors of hyperlipoproteinemia. Zeitschrift fur Die Gesamte Innere Medizin und Ihre Grenzgebiete
1977;32:1248.
[13] Musso G, Gambino R, Bo S, et al. Should non-alcoholic fatty liver disease be
included in the denition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects.
Diabetes Care 2008;31:5628.
[14] Ferrannini E. Metabolic syndrome: a solution in search of a problem. Journal
of Clinical Endocrinology and Metabolism 2007;92:3968.
[15] Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. Journal of the American
College of Cardiology 2010;56:111332.

[16] Rachas A, Raffaitin C, Barberger-Gateau P, et al. Clinical usefulness of the

metabolic syndrome for the risk of coronary heart disease does not exceed the
sum of its individual components in older men and women. The Three-City
(3C) Study. Heart 2012;98:6505.
[17] Kawada T. Predictors of the development of metabolic syndrome in male
workers: a 3-year follow-up study. Journal of Occupational and Environmental Medicine 2012;54:2925.
[18] Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular
disease: a meta-analysis. American Journal of Medicine 2006;119:8129.
[19] Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the
risk of primary liver cancer in the United States: a study in the SEER-Medicare
database. Hepatology 2011;54:46371.
[20] Lonardo A. Fatty liver and non-alcoholic steatohepatitis. Where do we stand
and where are we going? Digestive Diseases 1999;17:809.
[21] Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of non-alcoholic
fatty liver disease with insulin resistance. American Journal of Medicine
1999;107:4505.
[22] Cortez-Pinto H, Camilo ME, Baptista A, et al. Non-alcoholic fatty liver: another
feature of the metabolic syndrome? Clinical Nutrition 1999;18:3538.
[23] Vanni E, Bugianesi E, Kotronen A, et al. From the metabolic syndrome to NAFLD
or vice versa? Digestive and Liver Disease 2010;42:32030.
[24] Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus,
cardiovascular disease or cirrhosis. Nature Reviews Gastroenterology & Hepatology 2013;10:33044.
[25] Machado MV, Cortez-Pinto H. Management of fatty liver disease with
the metabolic syndrome. Expert Review of Gastroenterology & Hepatology
2014;8:487500.
[26] Yki-Jrvinen H. Non-alcoholic fatty liver disease as a cause and a consequence
of metabolic syndrome. The Lancet Diabetes & Endocrinology 2014;2:90110.
[27] Lonardo A, Trande P. Are there any sex differences in fatty liver? A study of
glucose metabolism and body fat distribution. Journal of Gastroenterology
and Hepatology 2000;15:77582.
[28] Marchesini G, Brizi M, Bianchi G, et al. Non-alcoholic fatty liver disease: a
feature of the metabolic syndrome. Diabetes 2001;50:184450.
[29] Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-alcoholic fatty liver
disease and its association with impaired glucose metabolism in Japanese
adults. Diabetic Medicine 2005;22:11415.
[30] Wong VW, Hui AY, Tsang SW, et al. Prevalence of undiagnosed diabetes and
postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty
liver disease. Alimentary Pharmacology and Therapeutics 2006;24:121522.
[31] Gastaldelli A, Kozakova M, Hjlund K, et al. Fatty liver is associated with
insulin resistance, risk of coronary heart disease, and early atherosclerosis
in a large European population. Hepatology 2009;49:153744.
[32] Speliotes EK, Massaro JM, Hoffmann U, et al. Fatty liver is associated with
dyslipidemia and dysglycemia independent of visceral fat: the Framingham
Heart Study. Hepatology 2010;51:197987.
[33] Kim SH, Lee JW, Hwang HJ. Associations between combinations of body mass
index plus non-alcoholic fatty liver disease and diabetes mellitus among
Korean adults. Asia Pacic Journal of Clinical Nutrition 2011;20:1420.
[34] Bedogni G, Gastaldelli A, Manco M, et al. Relationship between fatty liver and
glucose metabolism: a cross-sectional study in 571 obese children. Nutrition,
Metabolism and Cardiovascular Diseases 2012;22:1206.
[35] Ortiz-Lopez C, Lomonaco R, Orsak B, et al. Prevalence of prediabetes and diabetes and metabolic prole of patients with non-alcoholic fatty liver disease
(NAFLD). Diabetes Care 2012;35:8738.
[36] Porter SA, Pedley A, Massaro JM, et al. Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin
resistance: the Framingham Heart Study. Arteriosclerosis, Thrombosis, and
Vascular Biology 2013;33:13946.
[37] Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of non-alcoholic fatty liver
disease in the United States: the Third National Health and Nutrition Examination Survey, 19881994. American Journal of Epidemiology 2013;178:
3845.
[38] Li X, Xia M, Ma H, et al. Liver fat content, evaluated through semi-quantitative
ultrasound measurement, is associated with impaired glucose proles: a
community-based study in Chinese. PLOS ONE 2013;8:e65210.
[39] Ou HY, Wang CY, Yang YC, et al. The association between non-alcoholic fatty
pancreas disease and diabetes. PLOS ONE 2013;8:e62561.
[40] Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatology
Research 2013;43:5164.
[41] Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of nonalcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive
tests for liver disease severity. Annals of Medicine 2011;43:61749.
[42] Ikai E, Noborizaka Y, Tsuritani I, et al. Serum gamma-glutamyl transpeptidase levels and hypertension in non-drinkers: a possible role of fatty
liver in the pathogenesis of obesity related hypertension. Obesity Research
1993;1:46974.
[43] Donati G, Stagni B, Piscaglia F, et al. Increased prevalence of fatty liver in
arterial hypertensive patients with normal liver enzymes: role of insulin
resistance. Gut 2004;53:10203.
[44] Lonardo A, Bellini M, Tartoni P, et al. The bright liver syndrome. Prevalence
and determinants of a bright liver echopattern. Italian Journal of Gastroenterology and Hepatology 1997;29:3516.
[45] Knobler H, Schattner A, Zhornicki T, et al. Fatty liver an additional and
treatable feature of the insulin resistance syndrome. QJM 1999 Feb;92:
739.

A. Lonardo et al. / Digestive and Liver Disease 47 (2015) 181190

[46] Marchesini G, Avagnina S, Barantani EG, et al. Aminotransferase and
gamma-glutamyltranspeptidase levels in obesity are associated with insulin
resistance and the metabolic syndrome. Journal of Endocrinological Investigation 2005;28:3339.
[47] Fan JG, Zhu J, Li XJ, et al. Fatty liver and the metabolic syndrome
among Shanghai adults. Journal of Gastroenterology and Hepatology
2005;20:182532.
[48] Kotronen A, Westerbacka J, Bergholm R, et al. Liver fat in the metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 2007;92:34907.
[49] Kawamoto R, Kohara K, Tabara Y, et al. Serum gamma-glutamyl transferase
levels are associated with metabolic syndrome in community-dwelling individuals. Journal of Atherosclerosis and Thrombosis 2009;16:35562.
[50] Anty R, Iannelli A, Patouraux S, et al. A new composite model including
metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the
diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Alimentary Pharmacology and Therapeutics 2010;32:131522.
[51] Xia MF, Yan HM, Lin HD, et al. Elevation of liver enzymes within the normal
limits and metabolic syndrome. Clinical and Experimental Pharmacology and
Physiology 2011;38:3739.
[52] Boursier J, Chaigneau J, Roullier V, et al. Steatosis degree, measured by
morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD. European Journal of Gastroenterology and
Hepatology 2011;23:97481.
[53] Hu X, Huang Y, Bao Z, et al. Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units. BMC Gastroenterology
2012;12:123.
[54] Pickhardt PJ, Jee Y, OConnor SD, et al. Visceral adiposity and hepatic steatosis
at abdominal CT: association with the metabolic syndrome. American Journal
of Roentgenology 2012;198:11007.
[55] Castro-Martnez MG, Banderas-Lares DZ, Ramrez-Martnez JC, et al. Prevalence of non-alcoholic fatty liver disease in subjects with metabolic syndrome.
Cirugia y Cirujanos 2012;80:12833.
[56] Kwon YM, Oh SW, Hwang SS, et al. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index
in Korean adults. American Journal of Gastroenterology 2012;107:18528.
[57] Sinn DH, Gwak GY, Park HN, et al. Ultrasonographically detected nonalcoholic fatty liver disease is an independent predictor for identifying
patients with insulin resistance in non-obese, non-diabetic middle-aged
Asian adults. American Journal of Gastroenterology 2012;107:5617.
[58] Younossi ZM, Stepanova M, Negro F, et al. Non-alcoholic fatty liver disease in
lean individuals in the United States. Medicine 2012;91:31927.
[59] Yousefzadeh G, Shokoohi M, Yeganeh M, et al. Role of gamma-glutamyl
transferase (GGT) in diagnosis of impaired glucose tolerance and metabolic
syndrome: a prospective cohort research from the Kerman Coronary
Artery Disease Risk Study (KERCADRS). Diabetology & Metabolic Syndrome
2012;6:1904.
[60] Soresi M, Noto D, Cefal AB, et al. Non-alcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis
society. Acta Diabetologica 2013;50:2419.
[61] Smits MM, Ioannou GN, Boyko EJ, et al. Non-alcoholic fatty liver disease as
an independent manifestation of the metabolic syndrome: results of a US
national survey in three ethnic groups. Journal of Gastroenterology and Hepatology 2013;28:66470.
[62] Eraslan S, Kizilgul M, Uzunlulu M, et al. Frequency of metabolic syndrome
and 25-hydroxyvitamin D3 levels in patients with non-alcoholic fatty liver
disease. Minerva Medica 2013;104:44753.
[63] Jurez-Rojas JG, Medina-Urrutia AX, Jorge-Galarza E, et al. Fatty liver increases
the association of metabolic syndrome with diabetes and atherosclerosis.
Diabetes Care 2013;36:17268.
[64] Tao L, Li X, Zhu H, et al. Association between -glutamyl transferase and
metabolic syndrome: a cross-sectional study of an adult population in Beijing. International Journal of Environmental Research and Public Health
2013;10:552340.
[65] Fraser A, Harris R, Sattar N, et al. Alanine aminotransferase, gammaglutamyltransferase, and incident diabetes: the British Womens Heart and
Health Study and meta-analysis. Diabetes Care 2009;32:74150.
[66] Lonardo A, Loria P, Leonardi F, et al. Policentrica Steatosi Epatica Non Alcolica.
Fasting insulin and uric acid levels but not indices of iron metabolism are
independent predictors of non-alcoholic fatty liver disease. A casecontrol
study. Digestive and Liver Disease 2002;34:20411.
[67] Petta S, Camm C, Cabibi D, et al. Hyperuricemia is associated with histological
liver damage in patients with non-alcoholic fatty liver disease. Alimentary
Pharmacology and Therapeutics 2011;34:75766.
[68] Keenan T, Blaha MJ, Nasir K, et al. Relation of uric acid to serum levels of
high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis. American Journal of Cardiology
2012;110:178792.
[69] Ryu S, Song J, Choi BY, et al. Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30 to 39. Annals of Epidemiology
2007;17:24552.
[70] Sui X, Church TS, Meriwether RA, et al. Uric acid and the development of
metabolic syndrome in women and men. Metabolism: Clinical and Experimental 2008;57:84552.
[71] Lee JM, Kim HC, Cho HM, et al. Association between serum uric acid level
and metabolic syndrome. Journal of Preventive Medicine and Public Health
2012;45:1817.

187

[72] Zhang Q, Zhang C, Song X, et al. A longitudinal cohort based association study
between uric acid level and metabolic syndrome in Chinese Han urban male
population. BMC Public Health 2012;12:419.
[73] Wang JY, Chen YL, Hsu CH, et al. Predictive value of serum uric acid levels
for the diagnosis of metabolic syndrome in adolescents. Journal of Pediatrics
2012;161, 7536.e2.
[74] Lu W, Song K, Wang Y, et al. Relationship between serum uric acid and
metabolic syndrome: an analysis by structural equation modeling. Journal
of Clinical Lipidology 2012;6:15967.
[75] Yang T, Chu CH, Bai CH, et al. Uric acid level as a risk marker for metabolic
syndrome: a Chinese cohort study. Atherosclerosis 2012;220:52531.
[76] Zhang Z, Bian L, Choi Y. Serum uric acid: a marker of metabolic syndrome and
subclinical atherosclerosis in Korean men. Angiology 2012;63:4208.
[77] Goncalves JP, Oliveira A, Severo M, et al. Cross-sectional and longitudinal
associations between serum uric acid and metabolic syndrome. Endocrine
2012;4:4507.
[78] Hara S, Tsuji H, Ohmoto Y, et al. High serum uric acid level and low urine pH as
predictors of metabolic syndrome: a retrospective cohort study in a Japanese
urban population. Metabolism: Clinical and Experimental 2012;61:2818.
[79] Zhang ML, Gao YX, Wang X, et al. Serum uric acid and appropriate cut-off
value for prediction of metabolic syndrome among Chinese adults. Journal of
Clinical Biochemistry and Nutrition 2013;52:3842.
[80] Osgood K, Krakoff J, Thearle M. Serum uric acid predicts both current and
future components of the metabolic syndrome. Metabolic Syndrome and
Related Disorders 2013;11:15762.
[81] Ziaee A, Esmailzadehha N, Ghorbani A, et al. Association between uric acid
and metabolic syndrome in Qazvin Metabolic Diseases Study (QMDS), Iran.
Global Journal of Health Science 2012;5:15565.
[82] Cohen E, Krause I, Fraser A, et al. Hyperuricemia and metabolic syndrome:
lessons from a large cohort from Israel. Israel Medical Association Journal
2012;14:67680.
[83] Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for
non-alcoholic fatty liver disease. Journal of Hepatology 2008;48:9939.
[84] Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with brosis severity in patients with non-alcoholic fatty liver disease.
Hepatology 2010;51:196171.
[85] Basaranoglu M, Basaranoglu G, Sabuncu T, et al. Fructose as a key player in
the development of fatty liver disease. World Journal of Gastroenterology
2013;19:116672.
[86] Dhingra R, Sullivan L, Jacques PF, et al. Soft drink consumption and risk
of developing cardiometabolic risk factors and the metabolic syndrome in
middle-aged adults in the community. Circulation 2007;116:4808.
[87] Perez-Pozo SE, Schold J, Nakagawa T, et al. Excessive fructose intake induces
the features of metabolic syndrome in healthy adult men: role of uric acid in
the hypertensive response. International Journal of Obesity 2010;34:45461.
[88] Khitan Z, Kim DH. Fructose: a key factor in the development of
metabolic syndrome and hypertension. Journal of Nutrition and Metabolism
2013;2013:682673.
[89] Liangpunsakul S, Chalasani N. Is hypothyroidism a risk factor for nonalcoholic steatohepatitis? Journal of Clinical Gastroenterology 2003;37:
3403.
[90] Ittermann T, Haring R, Wallaschofski H, et al. Inverse association between
serum free thyroxine levels and hepatic steatosis: results from the Study of
Health in Pomerania. Thyroid 2012;22:56874.
[91] Chung GE, Kim D, Kim W, et al. Non-alcoholic fatty liver disease across the
spectrum of hypothyroidism. Journal of Hepatology 2012;57:1506.
[92] Carulli L, Ballestri S, Lonardo A, et al. Is non-alcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower
cholesterol levels? Internal and Emergency Medicine 2013;8:297305.
[93] Park HT, Cho GJ, Ahn KH, et al. Thyroid stimulating hormone is associated
with metabolic syndrome in euthyroid postmenopausal women. Maturitas
2009;62:3015.
[94] Ruhla S, Weickert MO, Arafat AM, et al. A high normal TSH is associated with
the metabolic syndrome. Clinical Endocrinology 2010;72:696701.
[95] Lai Y, Wang J, Jiang F, et al. The relationship between serum thyrotropin and
components of metabolic syndrome. Endocrine Journal 2011;58:2330.
[96] Heima NE, Eekhoff EM, Oosterwerff MM, et al. Thyroid function and the
metabolic syndrome in older persons: a population-based study. European Journal of Endocrinology/European Federation of Endocrine Societies
2012;168:5965.
[97] Waring AC, Rodondi N, Harrison S, et al. Thyroid function and prevalent and
incident metabolic syndrome in older adults: the Health, Ageing and Body
Composition Study. Clinical Endocrinology 2012;76:911.
[98] Trauner M, Claudel T, Fickert P, et al. Bile acids as regulators of hepatic lipid
and glucose metabolism. Digestive Diseases 2010;28:2204.
[99] Liechti F, Dufour JF. Treatment of NASH with ursodeoxycholic acid:
cons. Clinics and Research in Hepatology and Gastroenterology 2012;36:
S4652.
[100] Ratziu V. Treatment of NASH with ursodeoxycholic acid: pro. Clinics and
Research in Hepatology and Gastroenterology 2012;36:S415.
[101] Liaset B, Hao Q, Jrgensen H, et al. Nutritional regulation of bile acid
metabolism is associated with improved pathological characteristics of the
metabolic syndrome. Journal of Biological Chemistry 2011;286:2838295.
[102] Watanabe M, Morimoto K, Houten SM, et al. Bile acid binding resin improves
metabolic control through the induction of energy expenditure. PLoS ONE
2012;7:e38286.

188

A. Lonardo et al. / Digestive and Liver Disease 47 (2015) 181190

[103] Porez G, Prawitt J, Gross B, et al. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. Journal of Lipid Research
2012;53:172337.
[104] Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in
non-alcoholic fatty liver disease. Hepatology 2010;52:37081.
[105] Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise
reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011;60:127883.
[106] Bae JC, Suh S, Park SE, et al. Regular exercise is associated with a reduction
in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD
independent of obesity in Korean adults. PLoS ONE 2012;7:e46819.
[107] Keating SE, Hackett DA, George J, et al. Exercise and non-alcoholic fatty
liver disease: a systematic review and meta-analysis. Journal of Hepatology
2012;57:15766.
[108] Gerber L, Otgonsuren M, Mishra A, et al. Non-alcoholic fatty liver disease
(NAFLD) is associated with low level of physical activity: a population-based
study. Alimentary Pharmacology and Therapeutics 2012;36:77281.
[109] Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of
non-alcoholic fatty liver disease in adults: a systematic review. Journal of
Hepatology 2012;56:25566.
[110] Murer M, Schmied C, Battegay E, et al. Physical activity behaviour in patients
with metabolic syndrome. Swiss Medical Weekly 2012;142:w13691.
[111] Yamaoka K, Tango T. Effects of lifestyle modication on metabolic syndrome: a systematic review and meta-analysis. BMC Medicine 2012;10:
138.
[112] Hagns MP, Cederberg H, Mikkola I, et al. Reduction in metabolic syndrome
among obese young men is associated with exercise-induced body composition changes during military service. Diabetes Research and Clinical Practice
2012;98:3129.
[113] Kim JW, Kim DY. Effects of aerobic exercise training on serum sex hormone binding globulin, body fat index, and metabolic syndrome factors in
obese postmenopausal women. Metabolic Syndrome and Related Disorders
2012;10:4527.
[114] Nanri A, Tomita K, Matsushita Y, et al. Effect of six months lifestyle intervention in Japanese men with metabolic syndrome: randomized controlled trial.
Journal of Occupational Health 2012;54:21522.
[115] Gardner AW, Parker DE, Krishnan S, et al. Metabolic syndrome and daily
ambulation in children, adolescents, and young adults. Medicine and Science
in Sports and Exercise 2013;45:1639.
[116] Kim J, Tanabe K, Yoshizawa Y, et al. Lifestyle-based physical activity intervention for one year improves metabolic syndrome in overweight male
employees. Tohoku Journal of Experimental Medicine 2013;229:117.
[117] Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased
prevalence of suspected non-alcoholic fatty liver disease. Hepatology
2008;47:194754.
[118] Moriya A, Iwasaki Y, Ohguchi S, et al. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Alimentary Pharmacology and
Therapeutics 2011;33:37888.
[119] Dunn W, Sanyal AJ, Brunt EM, et al. Modest alcohol consumption is associated
with decreased prevalence of steatohepatitis in patients with non-alcoholic
fatty liver disease (NAFLD). Journal of Hepatology 2012;57:38491.
[120] Hamaguchi M, Kojima T, Ohbora A, et al. Protective effect of alcohol consumption for fatty liver but not metabolic syndrome. World Journal of
Gastroenterology 2012;18:15667.
[121] Carnethon MR, Loria CM, Hill JO, et al. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA)
study, 19852001. Diabetes Care 2004;27:270715.
[122] Wilsgaard T, Jacobsen BK. Lifestyle factors and incident metabolic syndrome. The Troms study 19792001. Diabetes Research and Clinical Practice
2007;78:217e24.
[123] Baik I, Shin C. Prospective study of alcohol consumption and metabolic syndrome. American Journal of Clinical Nutrition 2008;87:145563.
[124] Alkerwi A, Boutsen M, Vaillant M, et al. Alcohol consumption and the
prevalence of metabolic syndrome: a meta-analysis of observational studies.
Atherosclerosis 2009;204:62435.
[125] Baliunas DO, Taylor BJ, Irving H, et al. Alcohol as a risk factor for
type 2 diabetes: a systematic review and meta-analysis. Diabetes Care
2009;32:212332.
[126] Wakabayashi I. Cross-sectional relationship between alcohol consumption
and prevalence of metabolic syndrome in Japanese men and women. Journal
of Atherosclerosis and Thrombosis 2010;17:695704.
[127] Lee KW, Park BJ, Kang HT, et al. Alcohol-drinking patterns and metabolic
syndrome risk: the 2007 Korean national health and nutrition examination
survey. Alcohol 2011;45:499505.
[128] Sayon-Orea C, Martinez-Gonzalez MA, Bes-Rastrollo M. Alcohol consumption and body weight: a systematic review. Nutrition Reviews 2011;69:
41931.
[129] Kim BJ, Kim BS, Kang JH. Alcohol consumption and incidence of metabolic
syndrome in Korean men. A 3-year follow-up study. Circulation Journal
2012;76:236371.
[130] Chen CC, Lin WY, Li CI, et al. The association of alcohol consumption with
metabolic syndrome and its individual components: the Taichung community
health study. Nutrition Research 2012;32:249.
[131] Barrio-Lopez MT, Bes-Rastrollo M, Sayon-Orea C, et al. Different types of alcoholic beverages and incidence of metabolic syndrome and its components in
a Mediterranean cohort. Clinical Nutrition 2013;32:797804.

[132] Stoutenberg M, Lee DC, Sui X, et al. Prospective study of alcohol consumption
and the incidence of the metabolic syndrome in US men. British Journal of
Nutrition 2013;110:90110.
[133] Birerdinc A, Stepanova M, Pawloski L, et al. Caffeine is protective in patients
with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics 2012;35:7682.
[134] Molloy JW, Calcagno CJ, Williams CD, et al. Association of coffee and caffeine consumption with fatty liver disease, non-alcoholic steatohepatitis, and
degree of hepatic brosis. Hepatology 2012;55:42936.
[135] Anty R, Marjoux S, Iannelli A, et al. Regular coffee but not espresso drinking is protective against brosis in a cohort mainly composed of morbidly
obese European women with NAFLD undergoing bariatric surgery. Journal of
Hepatology 2012;57:10906.
[136] Gutirrez-Grobe Y, Chvez-Tapia N, Snchez-Valle V, et al. High coffee intake
is associated with lower grade non-alcoholic fatty liver disease: the role of
peripheral antioxidant activity. Annals of Hepatology 2012;11:3505.
[137] Masterton GS, Hayes PC. Coffee and the liver: a potential treatment
for liver disease? European Journal of Gastroenterology and Hepatology
2010;22:127783.
[138] Kalthoff S, Ehmer U, Freiberg N, et al. Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and
stomach. Gastroenterology 2010;139:1699710.
[139] Yamauchi R, Kobayashi M, Matsuda Y, et al. Coffee and caffeine ameliorate
hyperglycemia, fatty liver, and inammatory adipocytokine expression in
spontaneously diabetic KK-Ay mice. Journal of Agricultural and Food Chemistry 2010;58:5597603.
[140] Matsuda Y, Kobayashi M, Yamauchi R, et al. Coffee and caffeine improve
insulin sensitivity and glucose tolerance in C57BL/6J mice fed a high-fat diet.
Bioscience, Biotechnology, and Biochemistry 2011;75:230915.
[141] Carrieri MP, Sogni P, Cohen J, et al. HEPAVIH Study Group. Elevated coffee
consumption and reduced risk of insulin resistance in HIV-HCV coinfected
patients (HEPAVIH ANRS CO-13). Hepatology 2012;56:2010.
[142] Sugiura C, Nishimatsu S, Moriyama T, et al. Catechins and caffeine inhibit fat
accumulation in mice through the improvement of hepatic lipid metabolism.
Journal of Obesity 2012;2012:520510.
[143] Hino A, Adachi H, Enomoto M, et al. Habitual coffee but not green tea
consumption is inversely associated with metabolic syndrome: an epidemiological study in a general Japanese population. Diabetes Research and Clinical
Practice 2007;76:3839.
[144] Panchal SK, Wong WY, Kauter K, et al. Caffeine attenuates metabolic syndrome in diet-induced obese rats. Nutrition 2012;28:105562.
[145] Takami H, Nakamoto M, Uemura H, et al. Inverse correlation between coffee
consumption and prevalence of metabolic syndrome: baseline survey of the
Japan Multi-Institutional Collaborative Cohort (J-MICC) Study in Tokushima,
Japan. Journal of Epidemiology 2013;23:1220.
[146] Hamabe A, Uto H, Imamura Y, et al. Impact of cigarette smoking on onset of
non-alcoholic fatty liver disease over a 10-year period. Journal of Gastroenterology 2011;46:76978.
[147] Zein CO, Unalp A, Colvin R, et al. Non-alcoholic steatohepatitis clinical
research network. Smoking and severity of hepatic brosis in non-alcoholic
fatty liver disease. Journal of Hepatology 2011;54:7539.
[148] Koehler EM, Schouten JN, Hansen BE, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in the elderly: results from the Rotterdam study.
Journal of Hepatology 2012;57:130511.
[149] Sun K, Liu J, Ning G. Active smoking and risk of metabolic syndrome: a metaanalysis of prospective studies. PLoS ONE 2012;7:e47791.
[150] Hsieh SD, Muto T, Murase T, et al. Association of short sleep duration with
obesity, diabetes, fatty liver and behavioral factors in Japanese men. Internal
Medicine 2011;50:2499502.
[151] Aron-Wisnewsky J, Minville C, Tordjman J, et al. Chronic intermittent hypoxia
is a major trigger for non-alcoholic fatty liver disease in morbid obese. Journal
of Hepatology 2012;56:22533.
[152] Musso G, Cassader M, Olivetti C, et al. Association of obstructive sleep apnoea
with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obesity Reviews 2013;14:41731.
[153] Sookoian S, Gemma C, Fernndez Gianotti T, et al. Effects of rotating shift work
on biomarkers of metabolic syndrome and inammation. Journal of Internal
Medicine 2007;261:28592.
[154] Donga E, van Dijk M, van Dijk JG, et al. A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy
subjects. Journal of Clinical Endocrinology and Metabolism 2010;95:29638.
[155] Choi JK, Kim MY, Kim JK, et al. Association between short sleep duration and
high incidence of metabolic syndrome in midlife women. Tohoku Journal of
Experimental Medicine 2011;225:18793.
[156] Arora T, Jiang CQ, Thomas GN, et al. Self-reported long total sleep duration is
associated with metabolic syndrome: the Guangzhou Biobank Cohort Study.
Diabetes Care 2011;34:23179.
[157] Yilmaz Y, Ones T, Purnak T, et al. Association between the presence of brown
adipose tissue and non-alcoholic fatty liver disease in adult humans. Alimentary Pharmacology and Therapeutics 2011;34:31823.
[158] van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al. Coldactivated brown adipose tissue in healthy men. New England Journal of
Medicine 2009;360:15008.
[159] Cypess AM, Lehman S, Williams G, et al. Identication and importance of
brown adipose tissue in adult humans. New England Journal of Medicine
2009;360:150917.

A. Lonardo et al. / Digestive and Liver Disease 47 (2015) 181190

[160] Pasanisi F, Pace L, Fonti R, et al. Evidence of brown fat activity in constitutional
leanness. Journal of Clinical Endocrinology and Metabolism 2013;98:12148.
[161] Matsen ME, Thaler JP, Wisse BE, et al. In uncontrolled diabetes, thyroid hormone and sympathetic activators induce thermogenesis without increasing
glucose uptake in brown adipose tissue. American Journal of Physiology:
Endocrinology and Metabolism 2013;304:E73446.
[162] Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour
necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut
2001;48:20611.
[163] Nair S, Cope K, Risby TH, et al. Obesity and female gender increase
breath ethanol concentration: potential implications for the pathogenesis of non-alcoholic steatohepatitis. American Journal of Gastroenterology
2001;96:12004.
[164] Thuy S, Ladurner R, Volynets V, et al. Non-alcoholic fatty liver disease in
humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. Journal of Nutrition
2008;138:14525.
[165] Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and
tight junction alterations in non-alcoholic fatty liver disease. Hepatology
2009;49:187787.
[166] Harte AL, da Silva NF, Creely SJ, et al. Elevated endotoxin levels in nonalcoholic fatty liver disease. Journal of Inammation 2010;7:15.
[167] Verdam FJ, Rensen SS, Driessen A, et al. Novel evidence for chronic exposure to endotoxin in human non-alcoholic steatohepatitis. Journal of Clinical
Gastroenterology 2011;45:14952.
[168] Henao-Mejia J, Elinav E, Jin C, et al. Inammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012;482:17985.
[169] Machado MV, Cortez-Pinto H. Gut microbiota and non-alcoholic fatty liver
disease. Annals of Hepatology 2012;11:4409.
[170] Tremaroli V, Bckhed F. Functional interactions between the gut microbiota
and host metabolism. Nature 2012;489:2429.
[171] Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous
alcohol and NASH. Hepatology 2013;57:6019.
[172] Aron-Wisnewsky J, Gaborit B, Dutour A, et al. Gut microbiota and nonalcoholic fatty liver disease: new insights. Clinical Microbiology and Infection
2013;19:33848.
[173] Ley RE, Bckhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proceedings of the National Academy of Sciences of the United States
of America 2005;102:110705.
[174] Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:102731.
[175] Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes
associated with obesity. Nature 2006;444:10223.
[176] Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese
and lean twins. Nature 2009;457:4804.
[177] Schwiertz A, Taras D, Schfer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 2010;18:1905.
[178] Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control
inammation in obese mice through a mechanism involving GLP-2-driven
improvement of gut permeability. Gut 2009;58:1091103.
[179] Furet JP, Kong LC, Tap J, et al. Differential adaptation of human gut microbiota
to bariatric surgery-induced weight loss: links with metabolic and low-grade
inammation markers. Diabetes 2010;59:304957.
[180] Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered
gut microbiota in mice lacking Toll-like receptor 5. Science 2010;328:22831.
[181] Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. Journal
of Clinical Investigation 2011;121:212632.
[182] Greenblum S, Turnbaugh PJ, Borenstein E. Metagenomic systems biology of
the human gut microbiome reveals topological shifts associated with obesity
and inammatory bowel disease. Proceedings of the National Academy of
Sciences of the United States of America 2012;109:5949.
[183] Leber B, Tripolt NJ, Blattl D, et al. The inuence of probiotic supplementation on gut permeability in patients with metabolic syndrome: an open
label, randomized pilot study. European Journal of Clinical Nutrition 2012;66:
11105.
[184] Tehrani AB, Nezami BG, Gewirtz A, et al. Obesity and its associated disease: a
role for microbiota? Neurogastroenterology and Motility 2012;24:30511.
[185] Zupancic ML, Cantarel BL, Liu Z, et al. Analysis of the gut microbiota in
the old order Amish and its relation to the metabolic syndrome. PLoS ONE
2012;7:e43052.
[186] Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota
from lean donors increases insulin sensitivity in individuals with metabolic
syndrome. Gastroenterology 2012;143:9136.
[187] Parnell JA, Reimer RA. Prebiotic bres dose-dependently increase satiety hormones and alter Bacteroidetes and Firmicutes in lean and obese JCR:LA-cp
rats. British Journal of Nutrition 2012;107:60113.
[188] Caricilli AM, Saad MJ. The role of gut microbiota on insulin resistance. Nutrients 2013;5:82951.
[189] Targher G, Bertolini L, Scala L, et al. Associations between serum 25hydroxyvitamin D3 concentrations and liver histology in patients with
non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular
Diseases 2007;17:51724.
[190] Barchetta I, Carotti S, Labbadia G, et al. Liver vitamin D receptor. CYP2R1, and
CYP27A1 expression: relationship with liver histology and vitamin D3 levels

[191]

[192]

[193]
[194]
[195]

[196]
[197]

[198]
[199]

[200]

[201]

[202]
[203]
[204]
[205]
[206]

[207]

[208]

[209]
[210]

[211]

[212]

[213]

[214]
[215]

[216]

[217]

[218]

[219]
[220]

189

in patients with non-alcoholic steatohepatitis or hepatitis C virus. Hepatology

2012;56:21807.
Eliades M, Spyrou E, Agrawal N, et al. Meta-analysis: vitamin D and nonalcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics
2013;38:24654.
Adams LA, White SW, Marsh JA, et al. Association between liver-specic gene
polymorphisms and their expression levels with non-alcoholic fatty liver disease. Hepatology 2013;57:590600.
Kayaniyil S, Retnakaran R, Harris SB, et al. Prospective associations of vitamin
D with b-cell function and glycemia. Diabetes 2011;60:294753.
Ding C, Gao D, Wilding J, et al. Vitamin D signalling in adipose tissue. British
Journal of Nutrition 2012;108:191523.
Maki KC, Fulgoni VL, Keast DR, et al. Vitamin D intake and status are associated with lower prevalence of metabolic syndrome in U.S. adults: National
Health and Nutrition Examination Surveys 20032006. Metabolic Syndrome
and Related Disorders 2012;10:36372.
Wang C. Role of vitamin D in cardiometabolic diseases. Journal of Diabetes
Research 2013:243934.
Khan H, Kunutsor S, Franco OH, et al. Vitamin D, type 2 diabetes and other
metabolic outcomes: a systematic review and meta-analysis of prospective
studies. Proceedings of the Nutrition Society 2013;72:8997.
Kayaniyil S, Harris SB, Retnakaran R, et al. Prospective association of 25(OH)D
with metabolic syndrome. Clinical Endocrinology 2014;80:5027.
Tsatsoulis A, Mantzaris MD, Bellou S, et al. Insulin resistance: an adaptive mechanism becomes maladaptive in the current environment an
evolutionary perspective. Metabolism: Clinical and Experimental 2012;62:
62233.
Leclercq IA, Da Silva Morais A, Schroyen B, et al. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. Journal of
Hepatology 2007;47:14256.
Seki E, Brenner DA, Karin M. A liver full of JNK: signaling in regulation of cell
function and disease pathogenesis, and clinical approaches. Gastroenterology
2012;143:30720.
Hotamisligil GS. Endoplasmic reticulum stress and the inammatory basis of
metabolic disease. Cell 2010;140:90017.
Reaven GM. Banting lecture 1988: role of insulin resistance in human disease.
Diabetes 1988;37:1595607.
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet
2005;365:141528.
Loria P, Lonardo A, Carulli N. Should non-alcoholic fatty liver disease be
renamed? Digestive Diseases 2005;23:7282.
Hamaguchi M, Takeda N, Kojima T, et al. Identication of individuals with
non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic
syndrome. World Journal of Gastroenterology 2012;18:150816.
Lonardo A, Bellentani S, Ratziu V, et al. Insulin resistance in non-alcoholic
steatohepatitis: necessary but not sufcient death of a dogma from analysis of therapeutic studies? Expert Review of Gastroenterology & Hepatology
2011;5:27989.
Suzuki A, Angulo P, Lymp J, et al. Chronological development of elevated aminotransferases in a non-alcoholic population. Hepatology 2005;41:
6471.
Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic
pathway to chronic liver disease. Hepatology 2005;42:9871000.
Kotronen A, Yki-Jrvinen H. Fatty liver: a novel component of the
metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology
2008;28:2738.
Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves
hepatic steatosis but exacerbates liver damage and brosis in obese mice with
non-alcoholic steatohepatitis. Hepatology 2007;45:136674.
Lonardo A, Loria P, Carulli N. Insulin resistance in non-alcoholic fatty liver
disease: a clinical perspective. In: Leuschner U, James O, Dancygier H, editors. Falk symposium 121 steatohepatitis (NASH and ASH). Dordrecht, The
Netherlands: Kluwer; 2001. p. 10413.
Caldwell SH, Ikura Y, Iezzoni JC, et al. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty
liver)? Journal of Gastroenterology and Hepatology 2007;22:S119.
Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and
new insights. Science 2011;332:151923.
Riva MA, Riva E, Spicci M, et al. The city of Hepar: rituals, gastronomy, and
politics at the origins of the modern names for the liver. Journal of Hepatology
2011;55:11326.
Kumashiro N, Erion DM, Zhang D, et al. Cellular mechanism of insulin
resistance in non-alcoholic fatty liver disease. Proceedings of the National
Academy of Sciences of the United States of America 2011;108:163815.
Samuel VT, Liu ZX, Wang A, et al. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in non-alcoholic fatty liver disease. Journal of
Clinical Investigation 2007;117:73945.
Cantley JL, Yoshimura T, Camporez JP, et al. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic
insulin resistance. Proceedings of the National Academy of Sciences of the
United States of America 2013;110:186974.
Perry RJ, Samuel VT, Petersen KF, et al. The role of hepatic lipids in hepatic
insulin resistance and type 2 diabetes. Nature 2014;510:8491.
Zammit VA. Hepatic triacylglycerol synthesis and secretion: DGAT2 as
the link between glycaemia and triglyceridaemia. Biochemical Journal
2013;451:112.

190

A. Lonardo et al. / Digestive and Liver Disease 47 (2015) 181190

[221] Kasturiratne A, Weerasinghe S, Dassanayake AS, et al. Inuence of nonalcoholic fatty liver disease on the development of diabetes mellitus. Journal
of Gastroenterology and Hepatology 2013;28:1427.
[222] Ryan MC, Wilson AM, Slavin J, et al. Associations between liver histology and
severity of the metabolic syndrome in subjects with non-alcoholic fatty liver
disease. Diabetes Care 2005;28:12224.
[223] Loria P, Adinol LE, Bellentani S, et al. Practice guidelines for the diagnosis and
management of non-alcoholic fatty liver disease. A decalogue from the Italian
Association for the Study of the Liver (AISF) Expert Committee. Digestive and
Liver Disease 2010;42:27282.
[224] Smits MM, van Geenen EJ. The clinical signicance of pancreatic steatosis.
Nature Reviews Gastroenterology & Hepatology 2011;8:16977.
[225] Straub BK, Stoeffel P, Heid H, et al. Differential pattern of lipid dropletassociated proteins and de novo perilipin expression in hepatocyte
steatogenesis. Hepatology 2008;47:193646.
[226] Wanless IR, Shiota K. The pathogenesis of non-alcoholic steatohepatitis and
other fatty liver diseases: a four-step model including the role of lipid release
and hepatic venular obstruction in the progression to cirrhosis. Seminars in
Liver Disease 2004;24:99106.
[227] Greenberg AS, Coleman RA, Kraemer FB, et al. The role of lipid droplets in
metabolic disease in rodents and humans. Journal of Clinical Investigation
2011;121:210210.

[228] Lonardo A, Lombardini S, Scaglioni F, et al. Hepatic steatosis and insulin

resistance: does etiology make a difference? Journal of Hepatology
2006;44:1906.
[229] Amaro A, Fabbrini E, Kars M, et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia.
Gastroenterology 2010;139:14953.
[230] Ballestri S, Lonardo A, Losi L, et al. Do diabetes and obesity promote hepatic
brosis in familial heterozygous hypobetalipoproteinemia? Internal and
Emergency Medicine 2009;4:713.
[231] Kantartzis K, Machicao F, Machann J, et al. The DGAT2 gene is a candidate for
the dissociation between fatty liver and insulin resistance in humans. Clinical
Science (London) 2009;116:5317.
[232] Kantartzis K, Peter A, Machicao F, et al. Dissociation between fatty liver and
insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009;58:261623.
[233] Shen J, Wong GL, Chan HL, et al. PNPLA3 gene polymorphism accounts for
fatty liver in community subjects without metabolic syndrome. Alimentary
Pharmacology and Therapeutics 2014;39:5329.
[234] Sun Z, Lazar MA. Dissociating fatty liver and diabetes. Trends in Endocrinology
and Metabolism 2013;24:412.